<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 16 Jul 2024 18:12:27 +0000</lastbuilddate>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Intraplaque haemorrhage, coronary spasm, and resuscitated cardiac arrest in patients with non-obstructive coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae460. doi: 10.1093/eurheartj/ehae460. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011788</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae460>10.1093/eurheartj/ehae460</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011788</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeshi Nishi</dc:creator>
<dc:creator>Teruyoshi Kume</dc:creator>
<dc:creator>Yuichi Saito</dc:creator>
<dc:creator>Ken Kato</dc:creator>
<dc:creator>Kazuya Tateishi</dc:creator>
<dc:creator>Ryotaro Yamada</dc:creator>
<dc:creator>Hideki Kitahara</dc:creator>
<dc:creator>Yoji Neishi</dc:creator>
<dc:creator>Yoshio Kobayashi</dc:creator>
<dc:creator>Shiro Uemura</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intraplaque haemorrhage, coronary spasm, and resuscitated cardiac arrest in patients with non-obstructive coronary artery disease</dc:title>
<dc:identifier>pmid:39011788</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae460</dc:identifier>
</item>
<item>
<title>Cardiac wasting and cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae438. doi: 10.1093/eurheartj/ehae438. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae438>10.1093/eurheartj/ehae438</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011778</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Markus S Anker</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>José L Zamorano</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac wasting and cancer</dc:title>
<dc:identifier>pmid:39011778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae438</dc:identifier>
</item>
<item>
<title>Mechanical mitral valve obstruction: gone with the wind</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae431. doi: 10.1093/eurheartj/ehae431. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011683</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae431>10.1093/eurheartj/ehae431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011683</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Ping Hu</dc:creator>
<dc:creator>Xiao-Jing Ma</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mechanical mitral valve obstruction: gone with the wind</dc:title>
<dc:identifier>pmid:39011683</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae431</dc:identifier>
</item>
<item>
<title>Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify glucagon receptor signaling in cardiomyocytes as a critical determinant of HFpEF progression and provide proof-of-concept support for glucagon receptor antagonism as a potential therapy for the disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 16. doi: 10.1161/CIRCRESAHA.124.324706. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an emerging major unmet need and one of the most significant clinic challenges in cardiology. The pathogenesis of HFpEF is associated with multiple risk factors. Hypertension and metabolic disorders associated with obesity are the 2 most prominent comorbidities observed in patients with HFpEF. Although hypertension-induced mechanical overload has long been recognized as a potent contributor to heart failure with reduced ejection fraction, the synergistic interaction between mechanical overload and metabolic disorders in the pathogenesis of HFpEF remains poorly characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHOD: We investigated the functional outcome and the underlying mechanisms from concurrent mechanic and metabolic stresses in the heart by applying transverse aortic constriction in lean C57Bl/6J or obese/diabetic B6.Cg-Lep<sup>ob</sup>/J (ob/ob) mice, followed by single-nuclei RNA-seq and targeted manipulation of a top-ranked signaling pathway differentially affected in the 2 experimental cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In contrast to the post-trans-aortic constriction C57Bl/6J lean mice, which developed pathological features of heart failure with reduced ejection fraction over time, the post-trans-aortic constriction ob/ob mice showed no significant changes in ejection fraction but developed characteristic pathological features of HFpEF, including diastolic dysfunction, worsened cardiac hypertrophy, and pathological remodeling, along with further deterioration of exercise intolerance. Single-nuclei RNA-seq analysis revealed significant transcriptome reprogramming in the cardiomyocytes stressed by both pressure overload and obesity/diabetes, markedly distinct from the cardiomyocytes singularly stressed by pressure overload or obesity/diabetes. Furthermore, glucagon signaling was identified as the top-ranked signaling pathway affected in the cardiomyocytes associated with HFpEF. Treatment with a glucagon receptor antagonist significantly ameliorated the progression of HFpEF-related pathological features in 2 independent preclinical models. Importantly, cardiomyocyte-specific genetic deletion of the glucagon receptor also significantly improved cardiac function in response to pressure overload and metabolic stress.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify glucagon receptor signaling in cardiomyocytes as a critical determinant of HFpEF progression and provide proof-of-concept support for glucagon receptor antagonism as a potential therapy for the disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011638</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324706>10.1161/CIRCRESAHA.124.324706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011638</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Gao</dc:creator>
<dc:creator>Zhaojun Xiong</dc:creator>
<dc:creator>Yunxia Liu</dc:creator>
<dc:creator>Meng Wang</dc:creator>
<dc:creator>Menglong Wang</dc:creator>
<dc:creator>Tian Liu</dc:creator>
<dc:creator>Jianfang Liu</dc:creator>
<dc:creator>Shuxun Ren</dc:creator>
<dc:creator>Nancy Cao</dc:creator>
<dc:creator>Hai Yan</dc:creator>
<dc:creator>Daniel J Drucker</dc:creator>
<dc:creator>Christoph Daniel Rau</dc:creator>
<dc:creator>Tomohiro Yokota</dc:creator>
<dc:creator>Jijun Huang</dc:creator>
<dc:creator>Yibin Wang</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39011638</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324706</dc:identifier>
</item>
<item>
<title>Dysferlin Enables Tubular Membrane Proliferation in Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Dysferlin represents a new molecular target in cardiac disease that protects the integrity of tubule-sarcoplasmic reticulum junctional complexes for regulated excitation-contraction coupling and controls TAT network reorganization and tubular membrane proliferation in cardiomyocyte hypertrophy induced by pressure overload.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 16. doi: 10.1161/CIRCRESAHA.124.324588. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy compensates for increased biomechanical stress of the heart induced by prevalent cardiovascular pathologies but can result in cardiac failure if left untreated. We hypothesized that the tail-anchored protein dysferlin with multiple Ca<sup>2+</sup>-binding C<sub>2</sub>-domains is critical for the integrity of the transverse-axial tubule (TAT) network inside cardiomyocytes and contributes to the proliferation of TAT endomembranes during pressure overload-induced cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To reveal the impact of the membrane fusion and repair protein dysferlin on TAT network stabilization and proliferation necessary for the hypertrophic growth of cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Super-resolution light and electron microscopy of mouse cardiomyocytes identified a specific localization of dysferlin in a vesicular compartment in nanometric proximity to contact sites of the TAT network with the sarcoplasmic reticulum, a.k.a. junctional complexes for Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release. Mass spectrometry was used to characterize the cardiac dysferlin interactome, thereby identifying a novel protein interaction with the membrane-tethering sarcoplasmic reticulum protein juncophilin-2, a putative interactor of L-type Ca<sup>2+</sup> channels and ryanodine receptor Ca<sup>2+</sup> release channels in junctional complexes. While the dysferlin knockout caused a mild progressive phenotype of dilated cardiomyopathy in the mouse heart, global proteome analysis revealed changes preceding systolic failure. Following transverse aortic constriction, dysferlin protein expression was significantly increased in hypertrophied wild-type myocardium, while dysferlin knockout animals presented markedly reduced left-ventricular hypertrophy. Live-cell membrane imaging demonstrated a profound reorganization of the TAT network in wild-type left-ventricular myocytes post-transverse aortic constriction with robust proliferation of axial tubules, which critically depended on the increased expression of dysferlin within newly emerging tubule components.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dysferlin represents a new molecular target in cardiac disease that protects the integrity of tubule-sarcoplasmic reticulum junctional complexes for regulated excitation-contraction coupling and controls TAT network reorganization and tubular membrane proliferation in cardiomyocyte hypertrophy induced by pressure overload.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011635</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324588>10.1161/CIRCRESAHA.124.324588</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011635</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nora Josefine Paulke</dc:creator>
<dc:creator>Carolin Fleischhacker</dc:creator>
<dc:creator>Justus B Wegener</dc:creator>
<dc:creator>Gabriel C Riedemann</dc:creator>
<dc:creator>Constantin Cretu</dc:creator>
<dc:creator>Mufassra Mushtaq</dc:creator>
<dc:creator>Nina Zaremba</dc:creator>
<dc:creator>Wiebke Möbius</dc:creator>
<dc:creator>Yannik Zühlke</dc:creator>
<dc:creator>Jasper Wedemeyer</dc:creator>
<dc:creator>Lorenz Liebmann</dc:creator>
<dc:creator>Anastasiia A Gorshkova</dc:creator>
<dc:creator>Daniel Kownatzki-Danger</dc:creator>
<dc:creator>Eva Wagner</dc:creator>
<dc:creator>Tobias Kohl</dc:creator>
<dc:creator>Carolin Wichmann</dc:creator>
<dc:creator>Olaf Jahn</dc:creator>
<dc:creator>Henning Urlaub</dc:creator>
<dc:creator>Karl Toischer</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Tobias Moser</dc:creator>
<dc:creator>Julia Preobraschenski</dc:creator>
<dc:creator>Christof Lenz</dc:creator>
<dc:creator>Eva A Rog-Zielinska</dc:creator>
<dc:creator>Stephan E Lehnart</dc:creator>
<dc:creator>Sören Brandenburg</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Dysferlin Enables Tubular Membrane Proliferation in Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:39011635</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324588</dc:identifier>
</item>
<item>
<title>A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The DSP risk score is a novel model that leverages readily available clinical parameters to provide individualized VA risk assessment for DSP patients. This tool may help guide decision-making for primary prevention implantable cardioverter-defibrillator placement in this high-risk population and supports a gene-first risk stratification approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae409. doi: 10.1093/eurheartj/ehae409. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients from the multi-national DSP-ERADOS (Desmoplakin SPecific Effort for a RAre Disease Outcome Study) Network patient registry who had pathogenic or likely pathogenic DSP variants and no sustained VA prior to enrolment were followed longitudinally for the development of first sustained VA event. Clinically guided, step-wise Cox regression analysis was used to develop a novel clinical tool predicting the development of incident VA. Model performance was assessed by c-statistic in both the model development cohort (n = 385) and in an external validation cohort (n = 86).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 471 DSP patients [mean age 37.8 years, 65.6% women, 38.6% probands, 26% with left ventricular ejection fraction (LVEF) &lt; 50%] were followed for a median of 4.0 (interquartile range: 1.6-7.3) years; 71 experienced first sustained VA events {2.6% [95% confidence interval (CI): 2.0, 3.5] events/year}. Within the development cohort, five readily available clinical parameters were identified as independent predictors of VA and included in a novel DSP risk score: female sex [hazard ratio (HR) 1.9 (95% CI: 1.1-3.4)], history of non-sustained ventricular tachycardia [HR 1.7 (95% CI: 1.1-2.8)], natural logarithm of 24-h premature ventricular contraction burden [HR 1.3 (95% CI: 1.1-1.4)], LVEF &lt; 50% [HR 1.5 (95% CI: .95-2.5)], and presence of moderate to severe right ventricular systolic dysfunction [HR 6.0 (95% CI: 2.9-12.5)]. The model demonstrated good risk discrimination within both the development [c-statistic .782 (95% CI: .77-.80)] and external validation [c-statistic .791 (95% CI: .75-.83)] cohorts. The negative predictive value for DSP patients in the external validation cohort deemed to be at low risk for VA (&lt;5% at 5 years; n = 26) was 100%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The DSP risk score is a novel model that leverages readily available clinical parameters to provide individualized VA risk assessment for DSP patients. This tool may help guide decision-making for primary prevention implantable cardioverter-defibrillator placement in this high-risk population and supports a gene-first risk stratification approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011630</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae409>10.1093/eurheartj/ehae409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011630</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Richard T Carrick</dc:creator>
<dc:creator>Alessio Gasperetti</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Brittney Murray</dc:creator>
<dc:creator>Mikael Laredo</dc:creator>
<dc:creator>Iris van der Schaaf</dc:creator>
<dc:creator>Dennis Dooijes</dc:creator>
<dc:creator>Petros Syrris</dc:creator>
<dc:creator>Douglas Cannie</dc:creator>
<dc:creator>Crystal Tichnell</dc:creator>
<dc:creator>Nisha A Gilotra</dc:creator>
<dc:creator>Chiara Cappelletto</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Ardan M Saguner</dc:creator>
<dc:creator>Firat Duru</dc:creator>
<dc:creator>Robyn J Hylind</dc:creator>
<dc:creator>Dominic J Abrams</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Mattia Targetti</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Maddalena Graziosi</dc:creator>
<dc:creator>Moniek Cox</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Paolo Compagnucci</dc:creator>
<dc:creator>Michela Casella</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Claudio Tondo</dc:creator>
<dc:creator>Momina Yazdani</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Sanjay K Prasad</dc:creator>
<dc:creator>Leonardo Calò</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:creator>Sophie Hespe</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Harikrishna Tandri</dc:creator>
<dc:creator>Flavie Ader</dc:creator>
<dc:creator>Giovanni Peretto</dc:creator>
<dc:creator>Stacey Peters</dc:creator>
<dc:creator>Ari Horton</dc:creator>
<dc:creator>Jessica Yao</dc:creator>
<dc:creator>Eric Schulze-Bahr</dc:creator>
<dc:creator>Sven Dittman</dc:creator>
<dc:creator>Eric D Carruth</dc:creator>
<dc:creator>Katelyn Young</dc:creator>
<dc:creator>Maria Qureshi</dc:creator>
<dc:creator>Chris Haggerty</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Arthur Wilde</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Estelle Gandjbakhch</dc:creator>
<dc:creator>J Peter van Tintelen</dc:creator>
<dc:creator>Anneline S J M Te Riele</dc:creator>
<dc:creator>Perry Elliot</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Katherine C Wu</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</dc:title>
<dc:identifier>pmid:39011630</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae409</dc:identifier>
</item>
<item>
<title>Anticoagulation for transient atrial fibrillation post-coronary bypass: high quality evidence needed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae402. doi: 10.1093/eurheartj/ehae402. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011559</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae402>10.1093/eurheartj/ehae402</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011559</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation for transient atrial fibrillation post-coronary bypass: high quality evidence needed</dc:title>
<dc:identifier>pmid:39011559</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae402</dc:identifier>
</item>
<item>
<title>Sudden cardiac death risk stratification in heritable cardiomyopathies: phenotype-based to genotype-based risk scores</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae381. doi: 10.1093/eurheartj/ehae381. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39011555</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae381>10.1093/eurheartj/ehae381</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011555</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rafik Tadros</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sudden cardiac death risk stratification in heritable cardiomyopathies: phenotype-based to genotype-based risk scores</dc:title>
<dc:identifier>pmid:39011555</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae381</dc:identifier>
</item>
<item>
<title>Triaging early discharge for pulmonary embolism: home is where the heart(/lung) is</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39010836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae358. doi: 10.1093/eurheartj/ehae358. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39010836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39010836</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae358>10.1093/eurheartj/ehae358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39010836</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Triaging early discharge for pulmonary embolism: home is where the heart(/lung) is</dc:title>
<dc:identifier>pmid:39010836</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae358</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: The prognostic value of coronary inflammation in patients with non-obstructive coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39010255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae430. doi: 10.1093/eurheartj/ehae430. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39010255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39010255</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae430>10.1093/eurheartj/ehae430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39010255</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: The prognostic value of coronary inflammation in patients with non-obstructive coronary artery disease</dc:title>
<dc:identifier>pmid:39010255</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae430</dc:identifier>
</item>
<item>
<title>Cardiac involvement in Chagas disease and African trypanosomiasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39009679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>Trypanosomiases are diseases caused by various species of protozoan parasite in the genus Trypanosoma, each presenting with distinct clinical manifestations and prognoses. Infections can affect multiple organs, with Trypanosoma cruzi predominantly affecting the heart and digestive system, leading to American trypanosomiasis or Chagas disease, and Trypanosoma brucei primarily causing a disease of the central nervous system known as human African trypanosomiasis or sleeping sickness. In this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 15. doi: 10.1038/s41569-024-01057-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Trypanosomiases are diseases caused by various species of protozoan parasite in the genus Trypanosoma, each presenting with distinct clinical manifestations and prognoses. Infections can affect multiple organs, with Trypanosoma cruzi predominantly affecting the heart and digestive system, leading to American trypanosomiasis or Chagas disease, and Trypanosoma brucei primarily causing a disease of the central nervous system known as human African trypanosomiasis or sleeping sickness. In this Review, we discuss the effects of these infections on the heart, with particular emphasis on Chagas disease, which continues to be a leading cause of cardiomyopathy in Latin America. The epidemiology of Chagas disease has changed substantially since 1990 owing to the emigration of over 30 million Latin American citizens, primarily to Europe and the USA. This movement of people has led to the global dissemination of individuals infected with T. cruzi. Therefore, cardiologists worldwide must familiarize themselves with Chagas disease and the severe, chronic manifestation - Chagas cardiomyopathy - because of the expanded prevalence of this disease beyond traditional endemic regions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39009679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39009679</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01057-3>10.1038/s41569-024-01057-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39009679</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ester Cerdeira Sabino</dc:creator>
<dc:creator>Maria Carmo P Nunes</dc:creator>
<dc:creator>Johannes Blum</dc:creator>
<dc:creator>Israel Molina</dc:creator>
<dc:creator>Antonio Luiz P Ribeiro</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiac involvement in Chagas disease and African trypanosomiasis</dc:title>
<dc:identifier>pmid:39009679</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01057-3</dc:identifier>
</item>
<item>
<title>Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>Our research investigates the societal implications of access to glucagon-like peptide-1 (GLP-1) agonists, particularly in light of recent clinical trials demonstrating the efficacy of semaglutide in reducing cardiovascular mortality. A decade-long analysis of Google Trends indicates a significant increase in searches for GLP-1 agonists, primarily in North America. This trend contrasts with the global prevalence of obesity. Given the high cost of GLP-1 agonists, a critical question arises: Will...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):171-173. doi: 10.1161/CIRCULATIONAHA.124.069680. Epub 2024 Jul 15.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Our research investigates the societal implications of access to glucagon-like peptide-1 (GLP-1) agonists, particularly in light of recent clinical trials demonstrating the efficacy of semaglutide in reducing cardiovascular mortality. A decade-long analysis of Google Trends indicates a significant increase in searches for GLP-1 agonists, primarily in North America. This trend contrasts with the global prevalence of obesity. Given the high cost of GLP-1 agonists, a critical question arises: Will this disparity in medication accessibility exacerbate the global health equity gap in obesity treatment? This viewpoint explores strategies to address the health equity gap exacerbated by this emerging medication. Because GLP-1 agonists hold the potential to become a cornerstone in obesity treatment, ensuring equitable access is a pressing public health concern.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008562</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069680>10.1161/CIRCULATIONAHA.124.069680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008562</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zahra Azizi</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Themistocles L Assimes</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide</dc:title>
<dc:identifier>pmid:39008562</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069680</dc:identifier>
</item>
<item>
<title>Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):250-252. doi: 10.1161/CIRCULATIONAHA.124.069582. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008561</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069582>10.1161/CIRCULATIONAHA.124.069582</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008561</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jelani K Grant</dc:creator>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Sui Zhang</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Roger S Blumenthal</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study</dc:title>
<dc:identifier>pmid:39008561</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069582</dc:identifier>
</item>
<item>
<title>Working to Promote Health Equity: The Fourth Annual Disparities Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):169-170. doi: 10.1161/CIRCULATIONAHA.124.070825. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008560</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070825>10.1161/CIRCULATIONAHA.124.070825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008560</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Latha Palaniappan</dc:creator>
<dc:creator>Karol Watson</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Working to Promote Health Equity: The Fourth Annual Disparities Issue</dc:title>
<dc:identifier>pmid:39008560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070825</dc:identifier>
</item>
<item>
<title>Dietary Acculturation Is Associated With Altered Gut Microbiome, Circulating Metabolites, and Cardiovascular Disease Risk in US Hispanics and Latinos: Results From HCHS/SOL</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among US Hispanic and Latino adults, greater dietary acculturation was associated with elevated CVD risk, possibly through alterations in gut microbiota and related metabolites. Diet and microbiota-targeted interventions may offer opportunities to mitigate CVD burdens of dietary acculturation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):215-229. doi: 10.1161/CIRCULATIONAHA.124.069824. Epub 2024 Jun 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dietary acculturation, or adoption of dominant culture diet by migrant groups, influences human health. We aimed to examine dietary acculturation and its relationships with cardiovascular disease (CVD), gut microbiota, and blood metabolites among US Hispanic and Latino adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the HCHS/SOL (Hispanic Community Health Study/Study of Latinos), US exposure was defined by years in the United States (50 states and Washington, DC) and US nativity. A dietary acculturation pattern was derived from 14 172 participants with two 24-hour dietary recalls at baseline (2008-2011) using least absolute shrinkage and selection operator regression, with food groups as predictors of US exposure. We evaluated associations of dietary acculturation with incident CVD across ≈7 years of follow-up (n=211/14 172 cases/total) and gut microbiota (n=2349; visit 2, 2014 to 2017). Serum metabolites associated with both dietary acculturation-related gut microbiota (n=694) and incident CVD (n=108/5256 cases/total) were used as proxy measures to assess the association of diet-related gut microbiome with incident CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified an empirical US-oriented dietary acculturation score that increased with US exposure. Higher dietary acculturation score was associated with higher risk of incident CVD (hazard ratio per SD, 1.33 [95% CI, 1.13-1.57]), adjusted for sociodemographic, lifestyle, and clinical factors. Sixty-nine microbial species (17 enriched from diverse species, 52 depleted mainly from fiber-utilizing <i>Clostridia</i> and <i>Prevotella</i> species) were associated with dietary acculturation, driven by lower intakes of whole grains, beans, and fruits and higher intakes of refined grains. Twenty-five metabolites, involved predominantly in fatty acid and glycerophospholipid metabolism (eg, branched-chain 14:0 dicarboxylic acid** and glycerophosphoethanolamine), were associated with both diet acculturation-related gut microbiota and incident CVD. Proxy association analysis based on these metabolites suggested a positive relationship between diet acculturation-related microbiome and risk of CVD (<i>r</i>=0.70, <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among US Hispanic and Latino adults, greater dietary acculturation was associated with elevated CVD risk, possibly through alterations in gut microbiota and related metabolites. Diet and microbiota-targeted interventions may offer opportunities to mitigate CVD burdens of dietary acculturation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069824>10.1161/CIRCULATIONAHA.124.069824</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008559</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Wang</dc:creator>
<dc:creator>Guo-Chong Chen</dc:creator>
<dc:creator>Zheng Wang</dc:creator>
<dc:creator>Kai Luo</dc:creator>
<dc:creator>Yanbo Zhang</dc:creator>
<dc:creator>Yang Li</dc:creator>
<dc:creator>Amanda C McClain</dc:creator>
<dc:creator>Marta M Jankowska</dc:creator>
<dc:creator>Krista M Perreira</dc:creator>
<dc:creator>Josiemer Mattei</dc:creator>
<dc:creator>Carmen R Isasi</dc:creator>
<dc:creator>Maria M Llabre</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Linda Van Horn</dc:creator>
<dc:creator>David Goldsztajn Farelo</dc:creator>
<dc:creator>Luis E Maldonado</dc:creator>
<dc:creator>Steven R Levine</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Rob Knight</dc:creator>
<dc:creator>Robert D Burk</dc:creator>
<dc:creator>Robert C Kaplan</dc:creator>
<dc:creator>Qibin Qi</dc:creator>
<dc:creator>Brandilyn A Peters</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dietary Acculturation Is Associated With Altered Gut Microbiome, Circulating Metabolites, and Cardiovascular Disease Risk in US Hispanics and Latinos: Results From HCHS/SOL</dc:title>
<dc:identifier>pmid:39008559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069824</dc:identifier>
</item>
<item>
<title>Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):243-245. doi: 10.1161/CIRCULATIONAHA.124.069083. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069083>10.1161/CIRCULATIONAHA.124.069083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008558</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nancy Song</dc:creator>
<dc:creator>Tariku J Beyene</dc:creator>
<dc:creator>Daniel K Amponsah</dc:creator>
<dc:creator>Steven M Asch</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes</dc:title>
<dc:identifier>pmid:39008558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069083</dc:identifier>
</item>
<item>
<title>Childhood Opportunity and Acute Interstage Outcomes: A National Pediatric Cardiology Quality Improvement Collaborative Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Zip code COI level is associated with differences in preoperative risk factors and stage 1 palliation hospitalization characteristics. Acute interstage outcomes, although common across the spectrum of childhood opportunity, are not associated with COI level in an era of highly prevalent home monitoring programs. The role of home monitoring in mitigating disparities during the interstage period merits further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):190-202. doi: 10.1161/CIRCULATIONAHA.124.069127. Epub 2024 Jun 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The interstage period after discharge from stage 1 palliation carries high morbidity and mortality. The impact of social determinants of health on interstage outcomes is not well characterized. We assessed the relationship between childhood opportunity and acute interstage outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Infants discharged home after stage 1 palliation in the National Pediatric Quality Improvement Collaborative Phase II registry (2016-2022) were retrospectively reviewed. Zip code-level Childhood Opportunity Index (COI), a composite metric of 29 indicators across education, health and environment, and socioeconomic domains, was used to classify patients into 5 COI levels. Acute interstage outcomes included death or transplant listing, unplanned readmission, intensive care unit admission, unplanned catheterization, and reoperation. The association between COI level and acute interstage outcomes was assessed using logistic regression with sequential adjustment for potential confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis cohort included 1837 patients from 69 centers. Birth weight (<i>P</i>&lt;0.001) and proximity to a surgical center at birth (<i>P</i>=0.02) increased with COI level. Stage 1 length of stay decreased (<i>P</i>=0.001), and exclusive oral feeding rate at discharge increased (<i>P</i>&lt;0.001), with higher COI level. More than 98% of patients in all COI levels were enrolled in home monitoring. Death or transplant listing occurred in 101 (5%) patients with unplanned readmission in 987 (53%), intensive care unit admission in 448 (24%), catheterization in 345 (19%), and reoperation in 83 (5%). There was no difference in the incidence or time to occurrence of any acute interstage outcome among COI levels in unadjusted or adjusted analysis. There was no interaction between race and ethnicity and childhood opportunity in acute interstage outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Zip code COI level is associated with differences in preoperative risk factors and stage 1 palliation hospitalization characteristics. Acute interstage outcomes, although common across the spectrum of childhood opportunity, are not associated with COI level in an era of highly prevalent home monitoring programs. The role of home monitoring in mitigating disparities during the interstage period merits further investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008557</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069127>10.1161/CIRCULATIONAHA.124.069127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008557</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Zielonka</dc:creator>
<dc:creator>Emily M Bucholz</dc:creator>
<dc:creator>Minmin Lu</dc:creator>
<dc:creator>Katherine E Bates</dc:creator>
<dc:creator>Garick D Hill</dc:creator>
<dc:creator>Nelangi M Pinto</dc:creator>
<dc:creator>Lynn A Sleeper</dc:creator>
<dc:creator>David W Brown</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Childhood Opportunity and Acute Interstage Outcomes: A National Pediatric Cardiology Quality Improvement Collaborative Analysis</dc:title>
<dc:identifier>pmid:39008557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069127</dc:identifier>
</item>
<item>
<title>Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Adding a collaborative care team to enhanced standard of care did not improve BP control but did improve patient ratings of chronic illness care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):230-242. doi: 10.1161/CIRCULATIONAHA.124.069622. Epub 2024 Jul 15.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Disparities in hypertension control are well documented but underaddressed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: RICH LIFE (Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone) was a 2-arm, cluster randomized trial comparing the effect on blood pressure (BP) control (systolic BP ≤140 mm Hg, diastolic BP ≤90 mm Hg), patient activation, and disparities in BP control of 2 multilevel interventions, standard of care plus (SCP) and collaborative care/stepped care (CC/SC). SCP included BP measurement standardization, audit and feedback, and equity-leadership training. CC/SC added roles to address social or medical needs. Primary outcomes were BP control and patient activation at 12 months. Generalized estimating equations and mixed-effects regression models with fixed effects of time, intervention, and their interaction compared change in outcomes at 12 months from baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1820 adults with uncontrolled BP and ≥1 other risk factors enrolled in the study. Their mean age was 60.3 years, and baseline BP was 152.3/85.5 mm Hg; 59.4% were women; 57.4% were Black, 33.2% were White, and 9.4% were Hispanic; 74% had hyperlipidemia; and 45.1% had type 2 diabetes. CC/SC did not improve BP control rates more than SCP. Both groups achieved statistically and clinically significant BP control rates at 12 months (CC/SC: 57.3% [95% CI, 52.7%-62.0%]; SCP: 56.7% [95% CI, 51.9%-61.5%]). Pairwise comparisons between racial and ethnic groups showed overall no significant differences in BP control at 12 months. Patients with coronary heart disease showed greater achievement of BP control in CC/SC than in SCP (64.0% [95% CI, 54.1%-73.9%] versus 50.8% [95% CI, 42.6%-59.0%]; <i>P</i>=0.04), as did patients in rural areas (67.3% [95% CI, 49.8%-84.8%] versus 47.8% [95% CI, 32.4%-63.2%]; <i>P</i>=0.01). Individuals in both arms experienced statistically and clinically significant reductions in mean systolic BP (CC/SC: -13.8 mm Hg [95% CI, -15.2 to -12.5]; SCP: -14.6 mm Hg [95% CI, -15.9 to -13.2]) and diastolic BP (CC/SC: -6.9 mm Hg [95% CI, -7.8 to -6.1]; SCP: -5.5 mm Hg [95% CI, -6.4 to -4.6]) over time. The difference in diastolic BP reduction between CC/SC and SCP over time was statistically significant (-1.4 mm Hg [95% CI, -2.6 to -0.2). Patient activation did not differ between arms. CC/SC showed greater improvements in patient ratings of chronic illness care (Patient Assessment of Chronic Illness Care score) over 12 months (0.12 [95% CI, 0.02-0.22]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Adding a collaborative care team to enhanced standard of care did not improve BP control but did improve patient ratings of chronic illness care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008556</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069622>10.1161/CIRCULATIONAHA.124.069622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008556</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lisa A Cooper</dc:creator>
<dc:creator>Jill A Marsteller</dc:creator>
<dc:creator>Kathryn A Carson</dc:creator>
<dc:creator>Katherine B Dietz</dc:creator>
<dc:creator>Romsai T Boonyasai</dc:creator>
<dc:creator>Carmen Alvarez</dc:creator>
<dc:creator>Deidra C Crews</dc:creator>
<dc:creator>Cheryl R Dennison Himmelfarb</dc:creator>
<dc:creator>Chidinma A Ibe</dc:creator>
<dc:creator>Lisa Lubomski</dc:creator>
<dc:creator>Edgar R Miller</dc:creator>
<dc:creator>Nae-Yuh Wang</dc:creator>
<dc:creator>Gideon D Avornu</dc:creator>
<dc:creator>Deven Brown</dc:creator>
<dc:creator>Debra Hickman</dc:creator>
<dc:creator>Michelle Simmons</dc:creator>
<dc:creator>Ariella Apfel Stein</dc:creator>
<dc:creator>Hsin-Chieh Yeh</dc:creator>
<dc:creator>RICH LIFE Project Investigators</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial</dc:title>
<dc:identifier>pmid:39008556</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069622</dc:identifier>
</item>
<item>
<title>"Asian" Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):177-179. doi: 10.1161/CIRCULATIONAHA.123.068576. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008555</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068576>10.1161/CIRCULATIONAHA.123.068576</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008555</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sang Gune K Yoo</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Nancy K Sweitzer</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>"Asian" Heart Failure</dc:title>
<dc:identifier>pmid:39008555</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068576</dc:identifier>
</item>
<item>
<title>Influence of Sex, Race and Ethnicity, and Deprivation on Survival and Completion of the Fontan Pathway for Children With Functionally Single Ventricle Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):246-249. doi: 10.1161/CIRCULATIONAHA.124.069779. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008554</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069779>10.1161/CIRCULATIONAHA.124.069779</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008554</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rachel L Knowles</dc:creator>
<dc:creator>Deborah Ridout</dc:creator>
<dc:creator>Qi Huang</dc:creator>
<dc:creator>Rodney C Franklin</dc:creator>
<dc:creator>Anna N Seale</dc:creator>
<dc:creator>Hannah Bellsham-Revell</dc:creator>
<dc:creator>Ferran Espuny-Pujol</dc:creator>
<dc:creator>Katherine L Brown</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Influence of Sex, Race and Ethnicity, and Deprivation on Survival and Completion of the Fontan Pathway for Children With Functionally Single Ventricle Heart Disease</dc:title>
<dc:identifier>pmid:39008554</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069779</dc:identifier>
</item>
<item>
<title>Advancing Cardiovascular Health Equity With Artificial Intelligence: A Collective Ethical Responsibility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240716141225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):174-176. doi: 10.1161/CIRCULATIONAHA.124.068113. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240716141225&v=2.18.0.post9+e462414">39008553</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068113>10.1161/CIRCULATIONAHA.124.068113</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008553</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Demilade Adedinsewo</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Advancing Cardiovascular Health Equity With Artificial Intelligence: A Collective Ethical Responsibility</dc:title>
<dc:identifier>pmid:39008553</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068113</dc:identifier>
</item>





























</channel>
</rss>